The stock of InflaRx N.V. (NASDAQ:IFRX) is a huge mover today! The stock increased 6.61% or $2.06 during the last trading session, reaching $33.22. About 58,988 shares traded. InflaRx N.V. (NASDAQ:IFRX) has risen 63.49% since February 15, 2018 and is uptrending. It has outperformed by 63.49% the S&P500. Some Historical IFRX News: 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating ResultsThe move comes after 5 months positive chart setup for the $852.50M company. It was reported on Feb, 15 by Barchart.com. We have $34.88 PT which if reached, will make NASDAQ:IFRX worth $42.62M more.
HAKUHODO DY HOLDINGS INC TOKYO ORDINARY (OTCMKTS:HKUOF) had an increase of 7.37% in short interest. HKUOF’s SI was 1.11 million shares in February as released by FINRA. Its up 7.37% from 1.03 million shares previously. It closed at $14.5 lastly. It is down 0.00% since February 15, 2018 and is . It has by 0.00% the S&P500.
Analysts await InflaRx N.V. (NASDAQ:IFRX) to report earnings on April, 4. After $-0.31 actual EPS reported by InflaRx N.V. for the previous quarter, Wall Street now forecasts 32.26% negative EPS growth.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $852.50 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Globenewswire.com which released: “Richard Brudnick to Join InflaRx Board of Directors – GlobeNewswire” on February 14, 2019, also Nasdaq.com with their article: “Factors Setting the Tone for Himax (HIMX) in Q4 Earnings – Nasdaq” published on February 15, 2019, Nasdaq.com published: “Pretivm Reports 2018 Results and 2019 Outlook – Nasdaq” on February 15, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “Verkkokauppa.com Oyj: Revenue grew by 22% during Q4 in a weak market – Nasdaq” published on February 15, 2019 as well as Nasdaq.com‘s news article titled: “UBISOFT ENTERTAINMENT : Ubisoft reports third-quarter 2018-19 sales – Nasdaq” with publication date: February 14, 2019.
Hakuhodo DY Holdings Inc., through its subsidiaries, engages in the provision of marketing and communications services to advertisers, media companies, and content holders in Japan and internationally. The company has market cap of $. It offers planning, production, marketing, public relations, and other services related to the presentation of advertising in various media, such as newspapers, magazines, radio, television, and digital media. It currently has negative earnings. The firm also provides brand development, brand building, sales promotion, and customer management services, as well as plans animation programs and live events.